2Gross ME,Shazer RL,Agus DB.Targeting the HER- kinase axis in cancer. Semin Oncol,2004,31(3):9
3Cunningham D,Humblet Y,Siena S et al . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan - refractory metastatic colorectal cancer. N Engl Med,2004,351:337
4Bonner J,Harari P, Giralt J et al . Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Eng I J Med,2006,354 (6):567
2Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab. Eurj Cancer, 2001, 37:S16-S22.
3Motzer RJ, Amato R, Todd M, et al. Phase Ⅱ trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Investigational New Drugs, 2003,21 (1): 99-101.
4Govindan R. Cetuximab in advanced non- small cell lung cancer.Clin Cancer Res, 2004, 10 (12) : 4241 - 4244.
5Henry QX, Arthur R, Albert L, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gerncitabine for advanced pancreatic cancer: a multicenter phase Ⅱ trial, J Clin Oncol, 2004, 22 (13): 2610- 2616.
6Saltz L. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 2004, 22(7): 1-8.
7Trigo J. Cetuximab (Erbitux (tm)) monotherapy is active in patients with platinum - refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol, 2004, 23: Abstract 1947.
8Van Cutsem E. An international phase Ⅱ study of cetuximab in combination with oxaliplatin/5 - fluoroucil (5 - FU) /folinic acid (FA) (FOLFOX-4) in the first- line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR): proc Eur Soc Med Oncol (ESMO),2004 : Abstract 339.
9Hoehler T. A phase Ⅰ/Ⅱ study of cetuximab (Erbitux (tm)) in combination with 5 - fluorouracil (5 - FU) /folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first- line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR). Preliminary results. Proc Eur Soc Med Oncol (ESMO), 2004: Abstract 262.
10David C, Yves H, Salvatore S, et al. Cetuxirnab rnonotherapy and cetuxirnab plus irinotecan in irinotecan - refractory metastatic colorectal cancer. New Engl J Med, 2004, 351 (4): 337-345.
1Saltz LB,Meropo NJ,Lcehrer PJ Sr,et al. Phase II trial of cetuximab in patientswith refractory colorectal cancer thatexpres-ses the epidermal growth factor receptor[J]. J Clin Onco,2004,22:1201-1208.
2Ciuleanu TE,Kurteva G,Ocvirk J,et al. A randomized,open-label- CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI+cetuximab as first-line therapy in patients(pts) with metastatic colorectal cancer(mCRC)[J]. J Clin Onco, 2008,26: a4032.
3Heinemann V, Fischer yon Weikersthal L, Vehling-Kaiser U, et al. Randomized trial comparing cetuximab plus XELIRI versus cetuxhnab plus XELOX as first line treatmentofpatientswithme-tastatic colorectal cancer (mCRC) :a study of the german AIO CRC study group[J]. J Chn Oncol, 2008,26(20 Suppl) : a4033.
4Grandis JR,Melhem MF,Barnes EL,et al. Quantitative immu-nohistochemical analysis of transforming growth factor-alpha andepidermal growth factor receptor in patients with squamous cellcarcinoma of the head and neck[J]. Cancer, 1996,78 : 1284-1292.
5Numico G,Colantonio I,Comino A,et al. EGFR and survival of patientswith locally advanced head and neck cancer (HNC)and treated with ahemating chemotherapy radiation (CT-RT):results of a retrospective analysis[J]. Proc Am Soc Clin Onco,2003,22:2018.
6Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies[J]. Crit Rev Oncol Hemato, 1995,19:183-232.
7Vermorken JB, Mesia R, Vega V,et al. Cetuximab extends survival of patientswith recurrent ormetastatic SCCHN when added to first line platinum based therapy:results of arandomized phase III (extreme)study (Abstr)[A]. ASCO annualmeeting[C],2007:6091.
8Bonner JA,Harari PM,Giralt J,et al. Radiotherapy plus cetux-imab for squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2006, 354(6) : 567-578.
9Suntharalingam M,Taylor R,Wolf J,et al. Early to:dcity and response, data from a Phase II trial of weekly eetuximab,CBDCA,paclitaxel,and daily RT in patients with locally advanced head and neck[J]. Int J Radiat Oncol Biol Phys, 2007,69(3 ) : s432.
10Bonner J,Harari P,Giralt J,et al. The relationship of cetuximab-induced rash and survival in patients with head and neck cancer treated with cetuximab and radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2004, 58(3):966-971.
